Breast cancers in monoallelic MUTYH germline mutation carriers have clinicopathological features overlapping with those in BRCA1 germline mutation carriers

被引:3
|
作者
Keske, Aysenur [1 ]
Weisman, Paul [1 ]
Ospina-Romero, Monica [1 ]
Raut, Prachi [1 ]
Smith-Simmer, Kelcy [2 ,3 ]
Zakas, Anna L. [2 ,3 ]
Flynn, Christopher [1 ]
Xu, Jin [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA
[2] Univ Wisconsin, Master Genet Counselor Studies, Acad Affairs, Sch Med & Publ Hlth, Madison, WI USA
[3] Univ Wisconsin, Oncol Genet, UW Hlth, Carbone Canc Ctr, Madison, WI USA
关键词
Hereditary breast cancer; MUTYH; Breast cancer with divergent grade/biomarker status; COLORECTAL-CANCER; RISK;
D O I
10.1007/s10549-023-07173-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Breast cancer patients referred to genetic counseling often undergo genetic testing with broad panels that include both breast cancer susceptibility genes as well as genes more specific for extramammary sites. As a result, patients are often incidentally found to have germline mutations in genes that are not necessarily related to breast cancer risk. One such gene is MUTYH. To understand the role MUTYH may play in breast cancer, the clinicopathological features of patients with monoallelic MUTYH germline mutation and breast cancer were examined.Methods The clinicopathological characteristics of the breast cancers from patients with monoallelic MUTYH mutation were compared to breast cancer patients with other germline mutations in known breast cancer susceptibility genes, including ATM, BRCA1/2, CHEK2, and PALB2. The breast cancer patients who received genetic counseling but tested negative for the aforementioned gene mutations were used as a control group.Results Histologic characteristics of the breast cancers arising in monoallelic MUTYH mutation carriers had significantly larger tumor size, higher tumor grade, and more high-risk biomarker profiles (i.e., Her2-positive and triple-negative) than breast cancer patients with susceptibility genes, except for BRCA1. MUTYH mutation carriers also showed a trend of more frequent intratumoral divergency in terms of tumor grade and biomarker profiles.Conclusion Although germline monoallelic MUTYH mutation is not thought to confer a meaningfully increased risk of breast cancer development, it may contribute to pathological aggressiveness and diversity of breast cancers when they sporadically arise in MUTYH carriers.
引用
收藏
页码:151 / 158
页数:8
相关论文
共 50 条
  • [31] Increased risk of contralateral breast cancer for BRCA1 mutation carriers compared to BRCA2 mutation carriers
    Graeser, M.
    Engel, C.
    Zaino, M.
    Schmutzler, R.
    ONKOLOGIE, 2008, 31 : 28 - 28
  • [32] Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
    Sunil R Lakhani
    Kum Kum Khanna
    Georgia Chenevix-Trench
    Breast Cancer Research, 12
  • [33] Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
    Lakhani, Sunil R.
    Khanna, Kum Kum
    Chenevix-Trench, Georgia
    BREAST CANCER RESEARCH, 2010, 12 (02)
  • [34] Characterization of estrogen receptor-positive breast cancers in BRCA1 mutation carriers
    Wang, Y.
    Collins, L.
    Schnitt, S.
    Garber, J.
    Tung, N.
    CANCER RESEARCH, 2009, 69 (02) : 137S - 137S
  • [35] Correction: Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
    Kengo Ikejima
    Sayuri Tokioka
    Kazuyo Yagishita
    Yuka Kajiura
    Naoki Kanomata
    Hideko Yamauchi
    Yasuyuki Kurihara
    Hiroko Tsunoda
    Journal of Medical Ultrasonics, 2023, 50 : 589 - 589
  • [36] Analysis of tumor immunogenicity in germline BRCA1/2 mutation associated breast and ovarian cancers
    Kraya, Adam
    Maxwell, Kara N.
    Wenz, Brandon M.
    Wubbenhorst, Bradley
    De Sloover, Daniel
    Lunceford, Nicole
    Barrett, Amanda
    Morrissette, Jennifer D.
    Feldman, Michael
    Vonderheide, Robert H.
    Domcheck, Susan M.
    Nathanson, Katherine L.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [37] Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers
    Lee, Young-Jae
    Lee, Shin-Wha
    Kim, Kyu-Rae
    Jung, Kyung-Hae
    Lee, Jong-Won
    Kim, Yong-Man
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (01)
  • [38] Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
    Tung, Nadine
    Wang, Yihong
    Collins, Laura C.
    Kaplan, Jennifer
    Li, Hailun
    Gelman, Rebecca
    Comander, Amy H.
    Gallagher, Bridget
    Fetten, Katharina
    Krag, Karen
    Stoeckert, Kathryn A.
    Legare, Robert D.
    Sgroi, Dennis
    Ryan, Paula D.
    Garber, Judy E.
    Schnitt, Stuart J.
    BREAST CANCER RESEARCH, 2010, 12 (01)
  • [39] Survival in Norwegian BRCA1 mutation carriers with breast cancer
    Hagen, Anne Irene
    Tretli, Steinar
    Maehle, Lovise
    Apold, Jaran
    Veda, Nina
    Moller, Pal
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2009, 7
  • [40] Management of breast cancer in BRCA1/2 mutation carriers
    Eeles, RA
    Camplejohn, R
    Peacock, J
    McMillan, T
    DISEASE MARKERS, 1999, 15 (1-3) : 204 - 204